MindRank Pharma to Present at SAPA-China 2024 Pharmaceutical Industry Conference

October 18-19, 2024, SAPA-China 2024 Pharmaceutical Industry Conference will be held in"Suzhou Lion Mountain International Conference Center"Held. As a representative enterprise in China's AI pharmaceuticals field,"MindRank"Invited to attend this conference and will"October 19th, 14:40-15:05"Delivered a keynote speech at Sub-venue Four: "Artificial Intelligence Accelerates Innovative Drug Development" Forum.

MindRank's self-developed oral small molecule GLP-1 receptor agonist MDR-001 has officially enteredPhase IIb Clinical Study,The company will share the latest clinical progress of MDR-001 and the development status of its oncology drug pipeline at the conference.

For more information, please visit:

Countdown 6 Days! SAPA-China 2024 Pharmaceutical Industry Conference Invites You to Attend

SAPA is one of the largest biomedical professional organizations primarily composed of Chinese members active in both China and the U.S., with a 31-year history of development. The theme of this year's SAPA-China Pharmaceutical Industry Conference is "Promoting Innovation and Cooperation, Accelerating Industrial Integration," and it will bring together more than 7,000 scholars from top global research institutions as well as leading figures from large multinational pharmaceutical and biotech innovation companies.

The conference focuses on hot topics such as large/small molecules, cell and gene therapy, AI drug discovery, nucleic acids, GLP-1 and metabolism, clinical research, and international collaboration. It aims to connect the entire pharmaceutical industry chain from source innovation to applied research, clinical trials, regulation, production, and sales, while building an international exchange platform for the healthcare industry.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company's vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

MindRank's AI pharmaceutical solutions were rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 startups from mainland China making the list. In 2024, it was selected for Fortune magazine's IMPACT Enterprise List as one of "China's most socially influential startups."

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai